Karyopharm enters restructuring deal with Ayrmid

Item 7.01.

Regulation FD Disclosure.

On November 2, 2026, Karyopharm Therapeutics Inc. ("Karyopharm") issued a press release announcing that it entered into a Restructuring Support Agreement with its existing lenders and noteholders and other key stakeholders, which provides for a merger between Ayrmid Ltd. ("Ayrmid") and a reorganized Karyopharm (the "Transaction"). To implement the Transaction, Karyopharm has filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. The Company anticipates completing the Transaction through a Chapter 11 plan, and the Company will seek Court approval of bidding procedures, which will allow other parties to submit competing proposals and bids for the Company's assets. The Transaction is expected to close in the first quarter of 2027, subject to the conditions described in the Chapter 11 plan.¹ A copy of the press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.²

Cautionary Note Regarding Forward Looking Statements

The Company's securityholders are cautioned that trading in the Company's securities during the pendency of the Cases is highly speculative and poses substantial risks. Trading prices for the Company's securities may bear little or no relationship to the actual recovery, if any, by the Company's securityholders in the Cases. The Prepackaged Plan provides that holders of the Company's common stock and the Convertible Preferred Stock will not receive any payment or other distribution on account of such securities. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities. In particular, the Company expects that its existing equity securities will have no value and that holders of such securities will experience a complete loss on their investment.⁴

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits:

Exhibit 99.1 shall be deemed to be furnished and not filed:

Exhibit No.

Description

99.1

Press Release, dated November 2, 2026

104

Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KARYOPHARM THERAPEUTICS INC.

Date: November 2, 2026

By:

/s/ Michael Mano

Michael Mano

Executive Vice President, Chief Legal Officer and Secretary

Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future

– The Company Remains Focused on Supporting Patients and Advancing its Programs in Multiple Myeloma and Myelofibrosis –

– Ayrmid will Serve as Lead Bidder in Court-Supervised Sale Process to Maximize Business Value for all Stakeholders –

– The Company Receives a Commitment of $55 Million in Additional Financing and Ongoing Operations Are Expected to be Uninterrupted³

During Sale Process³ –

NEWTON, Mass., November 2, 2026 – Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm" or the "Company"), a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced today it has entered into a Restructuring Support Agreement with its existing lenders and noteholders and other key stakeholders, which provides for a merger between Ayrmid Ltd. ("Ayrmid") and a reorganized Karyopharm (the "Transaction"). During this process, Karyopharm remains focused on its commitment to advancing its multiple myeloma and myelofibrosis programs² and improving the lives of the patients Karyopharm serves and will continue to operate in the ordinary course of business.

To implement the Transaction, Karyopharm has filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Southern Di